BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/13/2020 5:45:32 AM | Browse: 756 | Download: 1323
 |
Received |
|
2020-07-09 18:03 |
|
Peer-Review Started |
|
2020-07-09 18:04 |
|
First Decision by Editorial Office Director |
|
2020-10-06 16:40 |
|
Return for Revision |
|
2020-10-06 16:40 |
|
Revised |
|
2020-10-20 03:46 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2020-11-11 09:48 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2020-11-12 17:02 |
|
Articles in Press |
|
2020-11-12 17:02 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2020-12-02 05:56 |
|
Publish the Manuscript Online |
|
2020-12-13 05:45 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, Research & Experimental |
| Manuscript Type |
Minireviews |
| Article Title |
SX-fraction: Promise for novel treatment of type 2 diabetes
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Sensuke Konno |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Sensuke Konno, PhD, Associate Professor, Department of Urology, New York Medical College, BSB Room A03, Valhalla, NY 10595, United States. sensuke_konno@nymc.edu |
| Key Words |
SX-fraction; Diabetes; Anti-diabetic; Hypoglycemic; Insulin signal pathway; |
| Core Tip |
We have been searching for a natural agent capable of controlling diabetic conditions in patients with type 2 diabetes for years. We then came across “SX-fraction (SXF)”, isolated from maitake mushroom (Grifola frondorsa), with anti-diabetic and hypoglycemic activities. In this short review, we chronologically described several key studies of SXF such as animal studies using diabetic mice (to demonstrate anti-diabetic activity), limited clinical studies on volunteer patients with type 2 diabetes (to show hypoglycemic activity), and in vitro study using skeletal muscle cells (to elucidate the hypoglycemic mechanism). After all, SXF appears to be a natural, safe, effective agent for treatment of patients with type 2 diabetes, although more (clinical) studies are yet required for confirmation. |
| Publish Date |
2020-12-13 05:45 |
| Citation |
Konno S. SX-fraction: Promise for novel treatment of type 2 diabetes. World J Diabetes 2020; 11(12): 572-583 |
| URL |
https://www.wjgnet.com/1948-9358/full/v11/i12/572.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v11.i12.572 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
